DEFA14A: XOMA Launches Tender Offer for LAVA Therapeutics

XOMA Royalty Corporation has commenced a tender offer to acquire LAVA Therapeutics N.V. for $1.16 to $1.24 per share plus a contingent value right.

Summary

• XOMA Royalty Corporation has initiated a tender offer to purchase all issued and outstanding common shares of LAVA Therapeutics N.V.
• The offer price consists of a Base Price Per Share of $1.16, an Additional Price Per Share of up to $0.08, and one Contingent Value Right (CVR) per share.
• The total cash consideration per share ranges from $1.16 to $1.24, plus the potential future payments from the CVR.
• The Purchase Agreement between LAVA and XOMA was dated August 3, 2025, and the tender offer commenced on August 15, 2025.
• LAVA has filed a Solicitation/Recommendation Statement on Schedule 14D-9, and XOMA has filed the Offer to Purchase and related documents with the SEC.
• An extraordinary general meeting (EGM) of LAVA shareholders will be convened at a later date to vote on proposed resolutions related to the transaction.

Sentiment

Score: 7

Explanation: The sentiment is generally positive due to a definitive acquisition offer providing a clear exit and cash value for shareholders. However, the CVR introduces uncertainty, and the transaction is subject to various closing conditions and risks, preventing a higher score.

Positives

• A definitive acquisition offer provides clarity and a potential liquidity event for LAVA shareholders.
• The offer includes a cash component of $1.16 to $1.24 per share, providing immediate value.
• The inclusion of a Contingent Value Right (CVR) offers shareholders potential upside from future events or milestones, subject to the CVR Agreement terms.

Negatives

• The Additional Price Per Share of up to $0.08 is not guaranteed and is subject to final determination.
• The value of the Contingent Value Right (CVR) is uncertain and may not result in any payments to shareholders.
• There is a risk that the transaction may not be completed in a timely manner, or at all, due to various closing conditions.

Risks

• Various closing conditions set forth in the Purchase Agreement may not be satisfied or waived, including uncertainties regarding the percentage of LAVA shareholders tendering their shares.
• The possibility that competing offers for LAVA may be made.
• The risk that the transactions may not be completed, which could adversely affect LAVA's business and share price.
• Significant costs associated with the transactions, including defense, indemnification, and liability from potential shareholder or other litigation.
• The risk that activities related to the CVR Agreement may not result in any value to LAVA's shareholders.
• Potential significant disruptions to LAVA's business due to transaction-related uncertainty prior to completion.
• The announcement and pendency of the transactions may make it more difficult for LAVA to establish or maintain relationships with employees, manufacturers, suppliers, vendors, or business partners.
• The occurrence of any event, change, or other circumstance that could lead to the termination of the Purchase Agreement.
• Potential adverse effects on LAVA's business condition and results from general economic and market conditions, including inflation, heightened interest rates, pandemics, and geopolitical conflicts.

Future Outlook

The company anticipates the completion of the proposed transaction, subject to various closing conditions, including shareholder tender rates and regulatory approvals. There is an expectation of potential payments to shareholders via the CVR Agreement, though this is not assured. A definitive proxy statement for an extraordinary general meeting will be filed at a later date to facilitate shareholder voting on transaction-related proposals.

Management Comments

• LAVA Therapeutics N.V. has entered into a share purchase agreement with XOMA Royalty Corporation.
• LAVA has concurrently filed a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC.
• LAVA intends to file a definitive proxy statement in connection with an extraordinary general meeting of shareholders to vote on EGM Proposals related to the transaction.

Industry Context

This tender offer represents a strategic acquisition in the biotechnology sector, a common occurrence as larger entities seek to expand their pipelines or acquire promising assets. Such transactions often reflect a consolidation trend or a strategic pivot by the acquiring company, XOMA, into specific therapeutic areas or technology platforms that LAVA Therapeutics may offer. The use of a CVR is also a common mechanism in biotech M&A to bridge valuation gaps and share future risks/rewards related to clinical or regulatory milestones.

Corporate Governance

Legal Proceedings

• The risk that any shareholder or other litigation in connection with the transactions may result in significant costs of defense, indemnification, and liability.

Stakeholder Impact

• Shareholders: Will receive cash consideration and a CVR for their shares, subject to the tender offer and EGM approval. They will need to make decisions regarding tendering shares and voting.
• Employees: LAVA's business may experience significant disruptions due to transaction-related uncertainty, potentially impacting employee morale and retention.
• Customers, Suppliers, Vendors, Business Partners: The announcement and pendency of the transactions may make it more difficult for LAVA to establish or maintain relationships with these parties.

Next Steps

• LAVA shareholders are urged to read the Offer Documents and the Schedule 14D-9 for more information.
• A definitive proxy statement with respect to the extraordinary general meeting (EGM) of LAVA shareholders will be filed at a later date.
• LAVA shareholders will vote on certain proposed resolutions (EGM Proposals) in connection with the transactions with XOMA.
• Investors and security holders should read the proxy statement and tender offer materials carefully when they become available before making any decision regarding tendering shares or voting.

Key Dates

Recommendation

A 'hold' recommendation is appropriate for LAVA Therapeutics shareholders at this stage. While a definitive tender offer has been made, shareholders need to thoroughly review the Offer to Purchase, the Schedule 14D-9, and the forthcoming definitive proxy statement for the EGM. The offer includes a contingent value right (CVR), whose value is uncertain, and the transaction is subject to various closing conditions. Holding allows investors to evaluate the full terms, potential CVR value, and any competing offers that might emerge, before making a decision to tender their shares or vote at the EGM.

Keywords

LAVA Therapeutics, XOMA Royalty Corporation, Tender Offer, Acquisition, Contingent Value Right, CVR, Merger, Biotechnology, Pharmaceuticals